Us­ing mon­ey hon­ey in­stead of threats, Sanofi wins a seat at the bar­gain­ing ta­ble for Medi­va­tion buy­out

It took a sweet­er bid and a CVR for its ex­per­i­men­tal ther­a­py ta­la­zoparib, but Sanofi $SNY can now take a seat at the bar­gain­ing ta­ble with Medi­va­tion $MD­VN in pur­suit of one of this year’s biggest biotech buy­outs.

Sanofi an­nounced this af­ter­noon that it pushed its bid to $58.00 a share – up from $52.50 – and added a $3.00 CVR for sales per­for­mance on ta­la­zoparib, Medi­va­tion’s block­buster bid for PARP in­hibitor glo­ry. That’s a po­ten­tial $11 bil­lion pay­out, up from the ini­tial $9.3 bil­lion of­fer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER